Drug Shows Promise in Delaying Type 1 Diagnosis
For the first time, researchers have delayed the onset of type 1 diabetes in people who are at high risk for it. The study included 76 close relatives of people with type 1, all of whom had high levels of antibodies associated with the disease and above-normal blood glucose levels—risk factors that make a future type 1 diabetes diagnosis almost guaranteed. Researchers randomly gave participants either a 14-day course of the experimental drug teplizumab, which affects the immune system, or a placebo, then followed them for an average of five years. By the end of the study, only 43 percent of those given teplizumab had developed type 1, compared with 72 percent who received the placebo. Overall, the drug delayed the onset of type 1 diabetes by about two years. The study was part of TrialNet, a research group that aims to prevent or delay type 1 diabetes. Find more information here.
Source: The New England Journal of Medicine, published online June 9, 2019